Rapport Therapeutics, Inc. Common Stock(RAPP)
Biotechnology
Neuroscience Biotech
| Filing Date | Insider | Type | 10b5-1 | Net Shares | Ownership change | Avg. Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | Third Rock Ventures V, L.P. 10% Owner | Sale | -18,572 | -0.29%6,280,525 | $40.05 | $743,753 | View SEC filing | |
| 2026-05-13 | Third Rock Ventures V, L.P. 10% Owner | Sale | -133,618 | -2.08%6,299,097 | $40.24 | $5,377,323 | View SEC filing | |
| 2026-05-11 | Third Rock Ventures V, L.P. 10% Owner | Sale | -276,513 | -4.12%6,432,715 | $40.12 | $11,094,906 | View SEC filing | |
| 2026-04-21 | Third Rock Ventures V, L.P. 10% Owner | Sale | -426,005 | -5.97%6,709,228 | $40.32 | $17,175,244 | View SEC filing | |
| 2026-04-21 | Yeleswaram Krishnaswamy Chief Development Officer | Sale | -20,225 | -7.58%246,426 | $39.99 | $808,844 | View SEC filing | |
| 2026-04-14 | Yeleswaram Krishnaswamy Chief Development Officer | Sale | -19,865 | -6.93%266,651 | $35.03 | $695,823 | View SEC filing | |
| 2026-04-09 | Yeleswaram Krishnaswamy Chief Development Officer | Sale | -360 | -0.13%286,516 | $34.90 | $12,564 | View SEC filing | |
| 2026-03-31 | Gault Cheryl Chief Operating Officer | Sale | -10,000 | -5.89%159,914 | $28.19 | $281,857 | View SEC filing | |
| 2026-03-26 | Yeleswaram Krishnaswamy Chief Development Officer | Sale | -10,115 | -3.41%286,876 | $29.99 | $303,355 | View SEC filing | |
| 2026-03-09 | Gault Cheryl Chief Operating Officer | Sale | -2,014 | -1.17%169,914 | $28.93 | $58,265 | View SEC filing | |
| 2026-02-19 | Ceesay Abraham Chief Executive Officer | Sale | -10,916 | -1.86%576,976 | $29.35 | $320,373 | View SEC filing | |
| 2026-02-19 | Bredt David Chief Scientific Officer | Sale | -8,500 | -2.15%387,075 | $29.02 | $246,655 | View SEC filing | |
| 2026-01-22 | Ceesay Abraham Chief Executive Officer | Sale | -10,916 | -1.82%587,892 | $26.11 | $285,071 | View SEC filing | |
| 2026-01-16 | Bredt David Chief Scientific Officer | Sale | -8,500 | -2.10%395,575 | $26.84 | $228,132 | View SEC filing | |
| 2026-01-05 | Bredt David Chief Scientific Officer | Sale | -6,567 | -1.60%404,075 | $30.05 | $197,338 | View SEC filing | |
| 2026-01-05 | Yeleswaram Krishnaswamy Chief Development Officer | Sale | -2,840 | -0.95%296,991 | $30.05 | $85,342 | View SEC filing | |
| 2025-12-18 | Ceesay Abraham Chief Executive Officer | Sale | -10,916 | -1.79%598,808 | $29.64 | $323,508 | View SEC filing | |
| 2025-12-16 | Bredt David Chief Scientific Officer | Sale | -8,500 | -2.12%392,642 | $30.02 | $255,130 | View SEC filing | |
| 2025-12-01 | Gault Cheryl Chief Operating Officer | Sale | -5,000 | -2.83%171,928 | $30.10 | $150,487 | View SEC filing | |
| 2025-11-18 | Ceesay Abraham Chief Executive Officer | Sale | -10,916 | -1.76%609,724 | $25.20 | $275,047 | View SEC filing | |
| 2025-11-18 | Bredt David Chief Scientific Officer | Sale | -8,500 | -2.07%401,142 | $25.19 | $214,091 | View SEC filing | |
| 2025-10-16 | Bredt David Chief Scientific Officer | Sale | -8,500 | -2.03%409,642 | $25.79 | $219,196 | View SEC filing | |
| 2025-10-16 | Ceesay Abraham Chief Executive Officer | Sale | -10,916 | -1.73%620,640 | $25.81 | $281,729 | View SEC filing | |
| 2025-09-19 | Ceesay Abraham Chief Executive Officer | Sale | -76,420 | -10.79%631,556 | $26.32 | $2,011,197 | View SEC filing | |
| 2025-09-17 | Bredt David Chief Scientific Officer | Sale | -8,500 | -1.99%418,142 | $24.19 | $205,649 | View SEC filing |
1-25 of 39